About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Silence of the Brain (Sudden Unexplained Death in Epilepsy)
Mashael Al.Khateeb1, Salah Baz1, Warren Blume2
1Division of Neurology, Department of Neuroscience, King Faisal Specialty Hospital and Research Center, Riyadh, Saudi Arabia; 2Department of Neuroscience, London Health Science Center, Western University, London, Ontario, Canada.
Corresponding Author:
Dr. Mashael Al.Khateeb
Email: kmashael@kfshrc.edu.sa
Received: 02-SEP-2015 Accepted: 23-NOV-2015 Published Online: 15-DEC-2015
DOI: http://dx.doi.org/10.17659/01.2015.0138
Abstract
Patients with medically refractory epilepsy have the highest risk for SUDEP (sudden unexpected death in epilepsy); 30%-50% of the patients are found dead in bed, often prone. SUDEP occurred in our case during EEG-video monitoring despite employment of all common protective measures. Intra-ictal cardiac dysrhythmias occurred in this patient suggesting that such may alarm caregivers of imminent SUDEP.
Keywords : Arrhythmias, Electroencephalography, Epilepsy, Heart Conduction System.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Jan 02, 2025